Company news
Ainos, Inc. news in 2022
Ainos, Inc.'s news releases, calls and decks from 2022, newest first.
Ainos Reports Unaudited Third Quarter 2022 Financial Results
November 6, 2022
Ainos Announces Positive Results from Additional Preclinical Study of Its Low-dose Oral Interferon Formulation Against New Variant Virus - Omicron
September 29, 2022
Ainos Submits Investigational New Drug Application to the U.S. FDA to Conduct Phase 2 Trial of its VELDONA Low-dose Oral Interferon Formulation Against Mild COVID-19 Symptoms
August 23, 2022
Ainos Announces Master Services Agreement with Swiss Pharmaceutical, Ltd. for Drug Testing, Manufacturing, and Packaging for its VELDONA Product Candidates
August 16, 2022
Ainos Reports Second Quarter 2022 Financial Results
August 14, 2022
Ainos Announces Closing of $3.3 Million Public Offering, Uplisting to NASDAQ, and Reverse Stock Split
August 10, 2022
Ainos Announces Pricing of $3.3 Million Public Offering, Uplisting to NASDAQ, and Reverse Stock Split
August 7, 2022
Ainos Announces Positive Results from Preclinical Studies of Its Low-dose Oral Interferon Formulation Against COVID-19
June 26, 2022
Ainos COVID-19 Antigen Self-Test Receives Approval for Sale in Taiwan
June 20, 2022